IVI & Germany

Partnership Highlights


German Leadership at IVI


Board of Trustees

Dr. Ralf Clemens, Principal and Founder of Grid Europe Consulting (2018- Present)


Scientific Advisory Group

Professor Fred Zepp, University Medical Center of the Johannes Gutenberg University Mainz (2018-2020)


Professor Stefan Kaufmann, Max Planck Institute for Infection Biology (2001; 2005-2006)


IVI Leadership Team

Dr. Florian Marks, Deputy Director General of Epidemiology, Public Health, Impact, and Clinical Development


Ongoing Collaboration with German Partners


Federal Ministry of Health (BMG)

The German Federal Ministry of Health is funding IVI’s Real-time Tracking of Neglected Bacterial Diseases and Resistance Patterns in Asia (TuNDRA) Plus program, which has identified the bacterial and viral etiology of febrile and respiratory diseases in hospitalized children and examined trends in bacterial antimicrobial resistance (AMR) in Bangladesh, Cambodia, and Vietnam


Robert Koch Institute

IVI collaborates with the Robert Koch Institute on the TuNDRA Plus program. 


Institute for Tropical Medicine at University Tübingen

IVI collaborates with the Institute for Tropical Medicine at University Tübingen on Vaccine Against Schistosomiasis for Africa (VASA), a consortium formed in 2019 by IVI and the University of Cambridge to assess the safety and immunogenicity of the SchistoShield® vaccine developed by PAI Life Sciences Inc. 


Bernhard Nocht Institute for Tropical Medicine

IVI collaborates with the Bernhard Nocht Institute on IVI’s Salmonella Vaccine Program, which aims to accelerate development of an injectable, trivalent vaccine for typhoid and invasive non-typhoidal Salmonella (iNTS).


In September 2018, IVI initiated preclinical work on the iNTS vaccine. Cell banks were generated for iNTS clinical isolates from IVI’s TSAP surveillance program that had been stored at the Bernhard Nocht Institute. 


Previous IVI-German Collaboration


Dengue Vaccines with the Federal Ministry of Education and Research (BMBF)

BMBF was a major donor to IVI from 2014 to 2018. BMBF provided grants to IVI’s Dengue Vaccine Initiative, which covered technical assistance and support to Instituto Butantan of Brazil and Vabiotech of Vietnam for the development of their dengue vaccine candidates.


North Korea Vaccination Campaign with Caritas Germany

In 2013, IVI supported a Japanese encephalitis vaccination campaign coordinated by Caritas Germany and the North Korean Ministry of Public Health (MOPH) in which over 3 million children were immunized. The campaign was part of IVI’s collaborated effort with the North Korean Academy of Medical Science (AMS) to reduce the burden of diarrheal disease and acute encephalitis syndrome (AES) among children in North Korea.


Else Kröner-Fresenius-Stiftung

In 2013, IVI received funding from the Else Kröner-Fresenius Foundation to conduct capacity-building activities in Burkina Faso and Madagascar, two of the Typhoid Surveillance in sub-Saharan Africa Program (TSAP) host countries. 


Sartorius AG

Sartorius AG was a major donor to IVI in the early years of its establishment, providing over €575,000 in funding to the Institute.


Sartorius AG sponsored IVI’s Annual International Course on Vaccinology (2004-2005) and annual training courses for professionals in developing countries on the clinical evaluation of vaccines. 


Sartorius AG was a donor to the Diseases of the Most Impoverished (DOMI) program, launched by IVI in 2000 with the aim of accelerating the development and introduction of vaccines against cholera, typhoid fever, and shigellosis in areas where these diseases are endemic.